Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-16
2007-10-16
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000
Reexamination Certificate
active
11196532
ABSTRACT:
Disclosed are compounds of formula A:and pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, R3, R21, A1, A2, X, and Z are as defined herein. Compounds of formula A are useful in the treatment of diseases and/or conditions related to cell differentiation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
REFERENCES:
patent: 5945431 (1999-08-01), Jin et al.
patent: 2002/0137733 (2002-09-01), Falardeau et al.
patent: 99/29318 (1999-06-01), None
Chan et al., Bioorganic & Medicinal Chemistry Letters, “Design and Synthesis of New Potent Human Cytomegalovirus (HCMV) Inhibitors Based on Internally Hydrogen-Bonded 1,6-Naphthyridines”, vol. 11, 2001, pp. 103-105.
Falardeau et al., Bioorganic & Medicinal Chemistry Letters, “Substituted 1,6-Naphthyridines as Human Cytomegalovirus Inhibitors: Conformational Requirements”, vol. 10, 2000, pp. 2769-2770.
Thompson et al., J. Chem. Soc., Perkin Trans. 1, “Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1H)-ones via diazotization of 3-aryl-1,6-naphthyridine-2,7-diamines”, 2000, pp. 1843-1852.
Chan et al., J. Med. Chem., “Discovery of 1,6-Naphthyridines as a Novel Class of Potent and Selective Human Cytomegalovirus Inhibitors”, vol. 42, 1999, pp. 3023-3025.
Keating et al., Biodrugs, “Infiximab an updated revies of its use in Crohn's disease and Rheumatoid arthritis”, 2002, vol. 16, pp. 111-148.
DeMartin et al., Arteriosclerosis, Thrombosis, and Vascular Biology, “The Transcription Faction NF-kappa B and the Regulation of Vascular Cell Function”, vol. 20, No. 11, 2000, pp. E83-E-88.
Orlowski et al., Trends in Molecular Medicine, “NF-kappa B as a Therapeutic Target in Cancer”, vol. 8, No. 8, 2002, pp. 385-389.
Bharti et al., Biochemical Pharmacology, “Nuclear Factor-Kappa B and Cancer: its Role in Prevention and Therapy”, vol. 64, No. 5-6, 2002, pp. 883-888.
Panwalkar et al., Cancer, “Nuclear Factor KappaB Modulations as a Therapeutic Approach in Hematologic Malignancies”, vol. 100, No. 8, Apr. 15, 2004, pp. 1578-1589.
Thompson et al., Journal of Medicinal Chemistry, American Chemical Society, Washington, US, “3-(3,5-Dimethoxphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase”, vol. 43, No. 22, 2000, pp. 4200-4211.
Barta Thomas E.
Hanson Gunnar J.
Huang He
Ware, Jr. Roy W.
McDonnell Boehnen & Hulbert & Berghoff LLP
Rahmani Niloofar
Seaman Margaret D.
Serenex, Inc.
LandOfFree
2,8-disubstituted naphthyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,8-disubstituted naphthyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,8-disubstituted naphthyridine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855709